RxDoctor Payments Data

Abigail Main, PA

Dermatology · Indianapolis, INNPI 1982285003

Payments from drug & device makers

$7,332in general payments, 2019–2025

Across 323 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$2K
  • Regeneron Healthcare Solutions, Inc.$847
  • Incyte Corporation$448
  • Sun Pharmaceutical Industries Inc.$372
  • Arcutis Biotherapeutics, Inc.$350
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$1,12515%
  • Food & beverage$6,10783%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,332 in reported general payments places this provider in the 60th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$63,975
Medicare patients
348
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast26$122,440
Dupixent PenDupilumab12$48,124
Clobetasol Propionate82$3,087
Tacrolimus16$1,892
Ketoconazole92$1,276
Fluorouracil18$1,081
Metronidazole18$952
Doxycycline Hyclate22$390
Triamcinolone Acetonide36$340
Mupirocin60$334
Mometasone Furoate16$267
Ciclopirox11$259
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$221
ValacyclovirValacyclovir Hcl12$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$24$122,44026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 202 dermatology providers in Indiana.

Other dermatology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →